News
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
Pentixapharm outlines new clinical development strategy focusing on CXCR4 therapeutic and diagnostic oncology programs, discontinuing PTF301 trial in MZL, preparing new trials in hematologic malignancies and Bladder Cancer -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE
Pentixapharm signs manufacturing agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE to produce CXCR4-targeting radiotherapeutic doses for clinical trials -